Cargando…
Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review
BACKGROUND: Immune-mediated demyelination and consequent degeneration of oligodendrocytes and axons are hallmark features of multiple sclerosis (MS). Remyelination declines in progressive MS, causing permanent axonal loss and irreversible disabilities. Strategies aimed at enhancing remyelination are...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688986/ https://www.ncbi.nlm.nih.gov/pubmed/33870797 http://dx.doi.org/10.1177/13524585211008760 |
_version_ | 1784618464838680576 |
---|---|
author | Allanach, Jessica R Farrell, John W. Mésidor, Miceline Karimi-Abdolrezaee, Soheila |
author_facet | Allanach, Jessica R Farrell, John W. Mésidor, Miceline Karimi-Abdolrezaee, Soheila |
author_sort | Allanach, Jessica R |
collection | PubMed |
description | BACKGROUND: Immune-mediated demyelination and consequent degeneration of oligodendrocytes and axons are hallmark features of multiple sclerosis (MS). Remyelination declines in progressive MS, causing permanent axonal loss and irreversible disabilities. Strategies aimed at enhancing remyelination are critical to attenuate disease progression. OBJECTIVE: We systematically reviewed recent advances in neuroprotective and regenerative therapies for MS, covering preclinical and clinical studies. METHODS: We searched three biomedical databases using defined keywords. Two authors independently reviewed articles for inclusion based on pre-specified criteria. The data were extracted from each study and assessed for risk of bias. RESULTS: Our search identified 7351 studies from 2014 to 2020, of which 221 met the defined criteria. These studies reported 262 interventions, wherein 92% were evaluated in animal models. These interventions comprised protein, RNA, lipid and cellular biologics, small molecules, inorganic compounds, and dietary and physiological interventions. Small molecules were the most highly represented strategy, followed by antibody therapies and stem cell transplantation. CONCLUSION: While significant strides have been made to develop regenerative treatments for MS, the current evidence illustrates a skewed representation of the types of strategies that advance to clinical trials. Further examination is thus required to address current barriers to implementing experimental treatments in clinical settings. |
format | Online Article Text |
id | pubmed-8688986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-86889862021-12-22 Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review Allanach, Jessica R Farrell, John W. Mésidor, Miceline Karimi-Abdolrezaee, Soheila Mult Scler Original Research Papers BACKGROUND: Immune-mediated demyelination and consequent degeneration of oligodendrocytes and axons are hallmark features of multiple sclerosis (MS). Remyelination declines in progressive MS, causing permanent axonal loss and irreversible disabilities. Strategies aimed at enhancing remyelination are critical to attenuate disease progression. OBJECTIVE: We systematically reviewed recent advances in neuroprotective and regenerative therapies for MS, covering preclinical and clinical studies. METHODS: We searched three biomedical databases using defined keywords. Two authors independently reviewed articles for inclusion based on pre-specified criteria. The data were extracted from each study and assessed for risk of bias. RESULTS: Our search identified 7351 studies from 2014 to 2020, of which 221 met the defined criteria. These studies reported 262 interventions, wherein 92% were evaluated in animal models. These interventions comprised protein, RNA, lipid and cellular biologics, small molecules, inorganic compounds, and dietary and physiological interventions. Small molecules were the most highly represented strategy, followed by antibody therapies and stem cell transplantation. CONCLUSION: While significant strides have been made to develop regenerative treatments for MS, the current evidence illustrates a skewed representation of the types of strategies that advance to clinical trials. Further examination is thus required to address current barriers to implementing experimental treatments in clinical settings. SAGE Publications 2021-04-19 2022-01 /pmc/articles/PMC8688986/ /pubmed/33870797 http://dx.doi.org/10.1177/13524585211008760 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Papers Allanach, Jessica R Farrell, John W. Mésidor, Miceline Karimi-Abdolrezaee, Soheila Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review |
title | Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review |
title_full | Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review |
title_fullStr | Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review |
title_full_unstemmed | Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review |
title_short | Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review |
title_sort | current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: a systematic review |
topic | Original Research Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688986/ https://www.ncbi.nlm.nih.gov/pubmed/33870797 http://dx.doi.org/10.1177/13524585211008760 |
work_keys_str_mv | AT allanachjessicar currentstatusofneuroprotectiveandneuroregenerativestrategiesinmultiplesclerosisasystematicreview AT farrelljohnw currentstatusofneuroprotectiveandneuroregenerativestrategiesinmultiplesclerosisasystematicreview AT mesidormiceline currentstatusofneuroprotectiveandneuroregenerativestrategiesinmultiplesclerosisasystematicreview AT karimiabdolrezaeesoheila currentstatusofneuroprotectiveandneuroregenerativestrategiesinmultiplesclerosisasystematicreview |